Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system

Authors:

Abstract
Objectives: Identify how many RA patients newly initiated on bDMARD therapy switch to another bDMARD during the first year of treatment; evaluate the factors and reasons associated with bDMARD switching; and compare the RA related healthcare resource utilization (HCRU) and costs between switchers versus non-switchers during the post-index period.Methods: A retrospective cohort study was conducted in RA patients using the Kaiser Permanente Southern California (KPSC) database with the study time period of 1-Jan-2007 to 31-Dec-2012. The index date was defined as the date of the first bDMARD prescription. Patients had to have continuous membership eligibility with drug benefit and no prior history of bDMARD during the 24 months prior index date. bDMARD switching was defined as a different bDMARD claim during post index. A multivariable logistic regression model was used to evaluate factors associated with switchers versus non-switchers. Chart notes were reviewed to evaluate reasons for switching from ...

This publication has 16 references indexed in Scilit: